EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Inhaled levodopa in Parkinson´s disease with motor fluctuations: post-commercialization experience in two movement disorders units

Pablo Ros-Arlanzón, Noelia Valverde-Mata, Maria-Luisa Almarcha-Menargues, Ángeles Patiño, Araceli Alonso-Cánovas, Paula Pérez-Torre, José Luis López-Sendón, Samira Fanjul, Mónica M Kurtis, Juan Carlos Martínez-Castrillo, Isabel Pareés

Neurological Sciences · 2026

DOI: 10.1007/s10072-026-09044-x ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Neurological Sciences, 2026. Verfasst von Pablo Ros-Arlanzón und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Dr. Balmis General University Hospital, Alicante, Spain. Hauptthemen laut MEDLINE: Parkinson Disease, Levodopa, Antiparkinson Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Oral levodopa is currently the most effective treatment for Parkinson’s disease (PD). However, many patients will suffer fluctuations as the disease progresses. CVT-301, an inhaled levodopa powder, has shown promise in clinical trials for managing OFF periods without severe side effects, yet real-world data are lacking. OBJECTIVES: To assess clinical effectiveness and tolerance of inhaled levodopa in PD patients. METHODS: observational study based on a retrospective chart review of consecutive PD patients treated with inhaled levodopa from April 2023 to May 2024. RESULTS: twenty-eight patients were included. Twenty (71.4%) reported improvement of OFF symptoms, with benefits appearing within 10 min in most patients. Adverse events were common. Only 2 (7.1%) discontinued treatment due to severe coughing. CONCLUSIONS: Inhaled levodopa offers rapid improvement in PD symptoms with acceptable tolerance. This real-world study underscores its potential benefit for PD-related fluctuations, widening on demand options for patients inadequately controlled by oral medications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseLevodopaAntiparkinson AgentsHumansAdministration, InhalationRetrospective StudiesFemaleAgedMaleMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

CVT-301Inhaled levodopaMotor fluctuationsParkinson’s disease

Substanzen

LevodopaAntiparkinson Agents

Autor:innen und Institutionen

  • Department of Neurology, Dr. Balmis General University Hospital, Alicante, Spain.
  • Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
  • Neurology Department, Badajoz University Hospital, Badajoz, Spain.
  • Movement Disorders Unit, Neurology Department, Hospital Ruber Internacional, Madrid, Spain.
  • Movement Disorders Unit, Neurology Department, Hospital Ramon y Cajal, Madrid, Spain.
  • Movement Disorders Unit, Neurology Department, Hospital Ruber Internacional, Madrid, Spain. Isabel.parees@salud.madrid.org.

Zitieren

APA

Ros-Arlanzón, P., Valverde-Mata, N., Almarcha-Menargues, M. L., Patiño, Á., Alonso-Cánovas, A., Pérez-Torre, P., López-Sendón, J. L., Fanjul, S., Kurtis, M. M., Martínez-Castrillo, J. C., & Pareés, I. (2026). Inhaled levodopa in Parkinson´s disease with motor fluctuations: post-commercialization experience in two movement disorders units. Neurological Sciences. https://doi.org/10.1007/s10072-026-09044-x

Vancouver

Ros-Arlanzón P, Valverde-Mata N, Almarcha-Menargues ML, Patiño Á, Alonso-Cánovas A, Pérez-Torre P, et al. Inhaled levodopa in Parkinson´s disease with motor fluctuations: post-commercialization experience in two movement disorders units. Neurological Sciences. 2026. doi:10.1007/s10072-026-09044-x

BibTeX
@article{RosArlanzn2026,
  author = {Ros-Arlanzón, Pablo and Valverde-Mata, Noelia and Almarcha-Menargues, Maria-Luisa and Patiño, Ángeles and Alonso-Cánovas, Araceli and Pérez-Torre, Paula and López-Sendón, José Luis and Fanjul, Samira and Kurtis, Mónica M and Martínez-Castrillo, Juan Carlos and Pareés, Isabel},
  title = {Inhaled levodopa in Parkinson´s disease with motor fluctuations: post-commercialization experience in two movement disorders units},
  journal = {Neurological Sciences},
  year = {2026},
  doi = {10.1007/s10072-026-09044-x}
}
Kostenlos starten →